To Study Treatment Resistance in High-Grade Serous Ovarian Cancer, MSK Researchers Develop New Approach
CloneSeq‑SV can track the evolution of treatment‑resistant subpopulations in high‑grade serous ovarian cancer, enabling earlier detection of resistance and informing personalized therapeutic strategies.
An innovative computational tool, CloneSeq‑SV, was developed to track tumor evolution and treatment resistance in high‑grade serous ovarian cancer by integrating single‑cell whole‑genome sequencing with targeted structural‑variant sequencing. The method was applied to longitudinal blood samples from 18 patients, revealing that resistant subpopulations were present at diagnosis and expanded after therapy. These findings highlight CloneSeq‑SV’s potential to guide personalized targeting of resistant clones and to inform future therapeutic strategies in ovarian cancer.
The ability to track resistant tumor subpopulations in real time allows clinicians to identify and target vulnerabilities before clinical relapse, potentially improving survival outcomes and reducing unnecessary exposure to ineffective therapies.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements